Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 3
1963 4
1964 14
1965 23
1966 17
1967 17
1968 35
1969 51
1970 63
1971 62
1972 91
1973 93
1974 84
1975 94
1976 80
1977 98
1978 91
1979 92
1980 97
1981 73
1982 88
1983 63
1984 88
1985 92
1986 88
1987 102
1988 88
1989 88
1990 136
1991 104
1992 87
1993 76
1994 91
1995 112
1996 52
1997 57
1998 65
1999 49
2000 44
2001 60
2002 41
2003 52
2004 36
2005 43
2006 46
2007 57
2008 38
2009 28
2010 44
2011 38
2012 38
2013 42
2014 40
2015 48
2016 51
2017 50
2018 35
2019 58
2020 62
2021 49
2022 42
2023 50
2024 43

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,730 results

Results by year

Filters applied: . Clear all
Page 1
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Kosoglou T, et al. Clin Pharmacokinet. 2005;44(5):467-94. doi: 10.2165/00003088-200544050-00002. Clin Pharmacokinet. 2005. PMID: 15871634 Review.
In contrast, coadministration with the bile acid binding agent colestyramine significantly decreased ezetimibe oral bioavailability (based on area under the plasma concentration-time curve of total ezetimibe). Hence, ezetimibe and colestyramine should be administere …
In contrast, coadministration with the bile acid binding agent colestyramine significantly decreased ezetimibe oral bioavailability ( …
Cholestyramine.
Thompson WG. Thompson WG. Can Med Assoc J. 1971 Feb 20;104(4):305-9. Can Med Assoc J. 1971. PMID: 5544698 Free PMC article. Review. No abstract available.
Cholestyramine.
[No authors listed] [No authors listed] Drug Ther Bull. 1968 Oct 11;6(21):81-2. Drug Ther Bull. 1968. PMID: 5698999 No abstract available.
Bile acid sequestrants.
Ast M, Frishman WH. Ast M, et al. J Clin Pharmacol. 1990 Feb;30(2):99-106. doi: 10.1002/j.1552-4604.1990.tb03447.x. J Clin Pharmacol. 1990. PMID: 2179278 Review.
The bile acid sequestrants, cholestyramine and colestipol, are the drugs of choice for the treatment of patients with hypercholesterolemia caused by increases in LDL-cholesterol levels without concurrent hypertriglyceridemia (type IIA and type IIB hyperlipoproteinemia). .. …
The bile acid sequestrants, cholestyramine and colestipol, are the drugs of choice for the treatment of patients with hypercholestero …
Clostridium difficile.
Pollok RC. Pollok RC. N Engl J Med. 2009 Feb 5;360(6):636; author reply 637-8. doi: 10.1056/NEJMc082396. N Engl J Med. 2009. PMID: 19196682 No abstract available.
Postcholecystectomy diarrhea.
Hutcheon DF, Bayless TM, Gadacz TR. Hutcheon DF, et al. JAMA. 1979 Feb 23;241(8):823-4. JAMA. 1979. PMID: 762849
All three patients' diarrhea resolved with cholestyramine resin therapy. This experience suggests that gallbladder removal may lead to a bile-acid-mediated diarrhea in some patients, and that this condition appears to respond to cholestyramine therapy....
All three patients' diarrhea resolved with cholestyramine resin therapy. This experience suggests that gallbladder removal may …
Cholestyramine for thyrotoxicosis?
Lin D, Suwantarat N, Bornemann M. Lin D, et al. J Fam Pract. 2013 Apr;62(4):E1-2. J Fam Pract. 2013. PMID: 23570035 No abstract available.
Integration of Metabolomics, Lipidomics, and Proteomics Reveals the Metabolic Characterization of Nonalcoholic Steatohepatitis.
Zhang J, Yang Y, Wang Z, Zhang X, Zhang Y, Lin J, Du Y, Wang S, Si D, Bao J, Tian X. Zhang J, et al. J Proteome Res. 2023 Aug 4;22(8):2577-2592. doi: 10.1021/acs.jproteome.3c00009. Epub 2023 Jul 5. J Proteome Res. 2023. PMID: 37403919
Moreover, the accumulation of bile acids (BAs) in NASH patients prompted us to investigate the protective effect of cholestyramine on NASH. The liver expression of essential proteins involved in FA transport and lipid droplets was significantly elevated in patients with NA …
Moreover, the accumulation of bile acids (BAs) in NASH patients prompted us to investigate the protective effect of cholestyramine on …
Cholestyramine in hypercholesterolaemia.
West R, Lloyd JK. West R, et al. Lancet. 1977 Feb 26;1(8009):488-9. doi: 10.1016/s0140-6736(77)91980-8. Lancet. 1977. PMID: 65596 No abstract available.
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease.
Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A, Yoneda M. Iwaki M, et al. Hepatol Commun. 2023 Oct 31;7(11):e0285. doi: 10.1097/HC9.0000000000000285. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37902528 Free PMC article.
Using a mouse model, we investigated the mechanism by which cholesterol exacerbates MASH and the effect of colestyramine (a bile acid adsorption resin) and elobixibat (an apical sodium-dependent bile acid transporter inhibitor) concomitant administration on bile aci …
Using a mouse model, we investigated the mechanism by which cholesterol exacerbates MASH and the effect of colestyramine (a bile acid …
3,730 results